Steffen Pabel
Harvard University(US)University Medical Center(US)Massachusetts General Hospital(US)
Publications by Year
Research Areas
Cardiac electrophysiology and arrhythmias, Diabetes Treatment and Management, Atrial Fibrillation Management and Outcomes, Ion channel regulation and function, Cardiovascular Function and Risk Factors
Most-Cited Works
- → Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation(2020)307 cited
- → Empagliflozin Reduces Ca/Calmodulin-Dependent Kinase II Activity in Isolated Ventricular Cardiomyocytes(2018)229 cited
- → Empagliflozin Directly Improves Diastolic Function in Human Heart Failure(2018)214 cited
- → Recruited macrophages elicit atrial fibrillation(2023)193 cited
- → SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?(2021)115 cited
- → Empagliflozin Inhibits Na+/H+ Exchanger Activity in Human Atrial Cardiomyocytes(2020)109 cited
- →